Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is positioned to succeed with a strong pipeline of clinical-stage assets targeting depressive and schizophrenia disorders using individual neurobiology to develop personalized and effective treatments. The company has a solid cash runway through 2029, and the Phase 2b study for ALTO-207 is now recruiting with data expected in 2H27. Additionally, the company has implemented trial-quality safeguards to improve the interpretability of upcoming data and is advanced under the 505(b)(2) pathway, further minimizing regulatory risk.

Bears say

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. Despite the company's promising pipeline and unique approach, there are several fundamental reasons for a negative outlook. These reasons include delays in the timing of top-line results for key clinical trials, high failure rates in depression research, unproven biomarker approach, reliance on third parties for supply and manufacturing, and the need for additional capital before profitability is achieved. These factors contribute to the company's high clinical and financial risks, making it difficult to accurately evaluate and assign a target price.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.